Author/Editor | Gelbrich, Goetz; Edelmann, Frank; Inkrot, Simone; Lainščak, Mitja; Apostolović, Svetlana; Neskovic, Aleksandar; Waagstein, Finn; Loeffler, Markus; Anker, Stefan D; Dietz, Rainer | |
Title | Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly | |
Type | članek | |
Source | Int J Cardiol | |
Vol. and No. | Letnik 155, št. 1 | |
Publication year | 2012 | |
Volume | str. 160-6 | |
Language | eng | |
Abstract | Background: Guideline-recommended beta-blocker (BB) target doses for patients with chronic heart failure can often not be reached. This secondary analysis of the CIBIS-ELD trial was carried out to better understand reasons for not achieving target doses. Methods: Changes in heart rate (HR) and other parameters during a 12-week up-titration period in 302 BB naive patients were evaluated in the subgroups achieving 12.5, 25, 50, and 100% of the target dose (groups 1, 2, 3, and 4, respectively). Results: Achieved doses predominantly depended on baseline HR (means 68, 74, 76, and 84bpm in groups 1-4, respectively, P<0.001). HR was consistently reduced with each dose level to 65, 63, and 62bpm in groups 1-3 and to 71bpm in group 4 (P<0.001). When adjusted for baseline, HR reduction achieved in group 3 was better than in group 4 (difference -5.4bpm, P<0.05). More patients in groups 3/4 than in groups 1/2 improved in NYHA class (P=0.01). NTproBNP increased by 38% in group 4 (P<0.01) but not in the others (P<0.05 between groups). Changes in blood pressure, six-minute walk distance and self-rated health were comparable in all groups. Conclusions: The desired effect of HR reduction appears to be a predominant limitation for BB up-titration. Vice versa, achieving the target dose may be a sign of insufficient response rather than successful treatment. In view of these results and the well-known importance of HR for survival, not target doses, but HR control should be given priority in BB treatment for heart failure. | |
Descriptors | HEART FAILURE, CONGESTIVE ADRENERGIC BETA-ANTAGONISTS HEART RATE FOLLOW-UP STUDIES AGED PRACTICE GUIDELINES |